Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. / Giovannoni, Gavin; Cook, Stuart; Rammohan, Kottil; Rieckmann, Peter; Sørensen, Per Soelberg; Vermersch, Patrick; Hamlett, Anthony; Viglietta, Vissia; Greenberg, Steven; CLARITY study group.

I: Lancet Neurology, Bind 10, Nr. 4, 2011, s. 329-37.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Giovannoni, G, Cook, S, Rammohan, K, Rieckmann, P, Sørensen, PS, Vermersch, P, Hamlett, A, Viglietta, V, Greenberg, S & CLARITY study group 2011, 'Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis', Lancet Neurology, bind 10, nr. 4, s. 329-37. https://doi.org/10.1016/S1474-4422(11)70023-0

APA

Giovannoni, G., Cook, S., Rammohan, K., Rieckmann, P., Sørensen, P. S., Vermersch, P., Hamlett, A., Viglietta, V., Greenberg, S., & CLARITY study group (2011). Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurology, 10(4), 329-37. https://doi.org/10.1016/S1474-4422(11)70023-0

Vancouver

Giovannoni G, Cook S, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P o.a. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurology. 2011;10(4):329-37. https://doi.org/10.1016/S1474-4422(11)70023-0

Author

Giovannoni, Gavin ; Cook, Stuart ; Rammohan, Kottil ; Rieckmann, Peter ; Sørensen, Per Soelberg ; Vermersch, Patrick ; Hamlett, Anthony ; Viglietta, Vissia ; Greenberg, Steven ; CLARITY study group. / Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. I: Lancet Neurology. 2011 ; Bind 10, Nr. 4. s. 329-37.

Bibtex

@article{801a69ca35f2479498a7594e43de8070,
title = "Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis",
abstract = "On the basis of various clinical and MRI measurements, the phase 3 Cladribine Tablets Treating Multiple Sclerosis Orally (CLARITY) study in patients with relapsing-remitting multiple sclerosis (RRMS) showed that short-course oral treatment with cladribine at cumulative doses of 3·5 and 5·25 mg/kg over 96 weeks was more effective than placebo. Achieving sustained freedom from disease activity is becoming a viable treatment goal in RRMS; we therefore aimed to assess the effects of cladribine on this composite outcome measure by doing a post-hoc analysis of data from the CLARITY study.",
author = "Gavin Giovannoni and Stuart Cook and Kottil Rammohan and Peter Rieckmann and S{\o}rensen, {Per Soelberg} and Patrick Vermersch and Anthony Hamlett and Vissia Viglietta and Steven Greenberg and S{\o}rensen, {Per Soelberg}",
note = "Copyright {\textcopyright} 2011 Elsevier Ltd. All rights reserved.",
year = "2011",
doi = "http://dx.doi.org/10.1016/S1474-4422(11)70023-0",
language = "English",
volume = "10",
pages = "329--37",
journal = "The Lancet Neurology",
issn = "1474-4422",
publisher = "TheLancet Publishing Group",
number = "4",

}

RIS

TY - JOUR

T1 - Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

AU - Giovannoni, Gavin

AU - Cook, Stuart

AU - Rammohan, Kottil

AU - Rieckmann, Peter

AU - Sørensen, Per Soelberg

AU - Vermersch, Patrick

AU - Hamlett, Anthony

AU - Viglietta, Vissia

AU - Greenberg, Steven

AU - CLARITY study group

N1 - Copyright © 2011 Elsevier Ltd. All rights reserved.

PY - 2011

Y1 - 2011

N2 - On the basis of various clinical and MRI measurements, the phase 3 Cladribine Tablets Treating Multiple Sclerosis Orally (CLARITY) study in patients with relapsing-remitting multiple sclerosis (RRMS) showed that short-course oral treatment with cladribine at cumulative doses of 3·5 and 5·25 mg/kg over 96 weeks was more effective than placebo. Achieving sustained freedom from disease activity is becoming a viable treatment goal in RRMS; we therefore aimed to assess the effects of cladribine on this composite outcome measure by doing a post-hoc analysis of data from the CLARITY study.

AB - On the basis of various clinical and MRI measurements, the phase 3 Cladribine Tablets Treating Multiple Sclerosis Orally (CLARITY) study in patients with relapsing-remitting multiple sclerosis (RRMS) showed that short-course oral treatment with cladribine at cumulative doses of 3·5 and 5·25 mg/kg over 96 weeks was more effective than placebo. Achieving sustained freedom from disease activity is becoming a viable treatment goal in RRMS; we therefore aimed to assess the effects of cladribine on this composite outcome measure by doing a post-hoc analysis of data from the CLARITY study.

U2 - http://dx.doi.org/10.1016/S1474-4422(11)70023-0

DO - http://dx.doi.org/10.1016/S1474-4422(11)70023-0

M3 - Journal article

VL - 10

SP - 329

EP - 337

JO - The Lancet Neurology

JF - The Lancet Neurology

SN - 1474-4422

IS - 4

ER -

ID: 40198084